Tedizolid for the management of human infections: in vitro characteristics.
about
Current and Future Considerations for the Treatment of Hospital-Acquired PneumoniaTedizolid Phosphate: a Next-Generation Oxazolidinone.Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections.Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infectionsProfile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infectionsA highly sensitive and efficient UPLC-MS/MS assay for rapid analysis of tedizolid (a novel oxazolidinone antibiotic) in plasma sample.Evolving resistance among Gram-positive pathogensIn Vitro Activities of Tedizolid and Linezolid against Gram-Positive Cocci Associated with Acute Bacterial Skin and Skin Structure Infections and Pneumonia.Prevalence and Abundance of Florfenicol and Linezolid Resistance Genes in Soils Adjacent to Swine Feedlots.Activity of Tedizolid in Methicillin-Resistant Staphylococcus aureus Experimental Foreign Body-Associated Osteomyelitis.Comparative In Vivo Efficacies of Tedizolid in Neutropenic versus Immunocompetent Murine Streptococcus pneumoniae Lung Infection Models.Activity of Tedizolid in Methicillin-Resistant Staphylococcus epidermidis Experimental Foreign Body-Associated Osteomyelitis.Methicillin-resistant Staphylococcus aureus pneumonia in adults.Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic.Recent developments in antibiotic agents for the treatment of complicated intra-abdominal infections.Antibiotic resistance in Staphylococcus aureus. Current status and future prospects.Oxazolidinone antimicrobials: a patent review (2012-2015).Recent Advances in the Rational Design and Optimization of Antibacterial Agents.Resistance to Non-glycopeptide Agents in Serious Staphylococcus aureus Infections.New agents approved for treatment of acute staphylococcal skin infectionsLinezolid: a promising option in the treatment of Gram-positives.Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infectionsIn Vitro Susceptibility Testing of Tedizolid against Nontuberculous Mycobacteria.Activities of Tedizolid and Linezolid Determined by the Reference Broth Microdilution Method against 3,032 Gram-Positive Bacterial Isolates Collected in Asia-Pacific, Eastern Europe, and Latin American Countries in 2014.Genetic environment of the transferable oxazolidinone/phenicol resistance gene optrA in Enterococcus faecalis isolates of human and animal origin.A novel gene, optrA, that confers transferable resistance to oxazolidinones and phenicols and its presence in Enterococcus faecalis and Enterococcus faecium of human and animal origin.Validation of a commercial dry-form broth microdilution device (Sensititre) for testing tedizolid, a new oxazolidinone.Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel oxazolidinone.In Vitro Susceptibility Testing of Tedizolid against Isolates of Nocardia.A metal-metalloporphyrin framework based on an octatopic porphyrin ligand for chemical fixation of CO2 with aziridines.Dosing strategies to optimize currently available anti-MRSA treatment options (Part 2: PO options).Binding and Action of Amino Acid Analogs of Chloramphenicol upon the Bacterial Ribosome.Mechanisms of Antibiotic Resistance.
P2860
Q28071882-C03453F2-82AF-4940-8205-F01CE5276369Q33420646-7358B491-8E48-4921-BCB8-280B4C702BB6Q33438834-3B866DC9-F72E-4D2F-B769-B22C1F7EAB9BQ35105971-19BB8B30-4670-45F0-BC0F-0A427FEAC1D0Q35542330-EC35747C-19CA-405C-AB61-AE4471C9AD02Q35997199-FF7FF158-1D20-44C9-9ACF-F215594F233AQ35999912-F2027DC8-EA5E-4145-B3B1-837A5E8F21C6Q36075813-1DFB60C1-3952-4634-8846-1E3E8B72B11EQ37215645-F38A7584-B7FD-4089-AFDC-B38623E92793Q37358626-77F874F2-54EE-45DB-AB28-65FFC847464AQ37538738-A829AA4A-6918-4245-B438-B1B233109409Q37613024-A2632B33-0BB9-4ADC-998C-CB4C43DAC1DAQ38230203-8A89DF12-ADC6-4999-A477-BD613B9D8223Q38352171-B8513323-B700-49DC-A737-9EDBC26DC1E9Q38536296-09DA07FE-425B-43EE-A078-4C0D82EA2953Q38648594-9C563762-0BD8-4CFD-8F39-32709531E479Q38728885-AB98362B-7977-419B-9E0A-D4D9CFFD1004Q38783047-5D6EF633-5C29-4B7E-8AC5-C462DF72BD7DQ38958278-E93E2E1F-06EF-496F-A408-777A881F7171Q39016281-F13105F6-D9D7-40AB-B2C2-21C339AA1A4BQ39025172-DECDA3B1-940E-4F3D-98FD-2B50F10ECE65Q39044932-FA621A80-98D8-4654-A402-422F65B70871Q39067666-6FBAEAFA-2B0F-433C-834E-912C706967A7Q40283050-B5FE5A98-4F60-41A5-A110-D5F5287A8999Q40633323-B887B414-139C-4D16-BB0E-BB90992DF20BQ40781736-1ABDCED8-7F98-4EA5-BB57-429C2B01EEE6Q40936787-5A51D8AA-5952-4358-8193-C759490203B7Q41655310-42B8636B-C11C-4F3B-83EB-8D8B4B87EF03Q41732849-4CD25527-9BD2-4D4E-992E-3746E81D8126Q46304818-DC2032B3-5202-4D4A-9809-76AE436235CEQ47230154-CA280356-5171-4187-A21F-453C8C8624A6Q47396324-390E2DE7-CB87-4066-B715-29EC359B2FC5Q50150775-60DEADBA-61BA-4266-931A-7C7AAEC2EEE5Q55387439-AA33E974-479F-443E-8DE4-F6DFAECCD52C
P2860
Tedizolid for the management of human infections: in vitro characteristics.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Tedizolid for the management of human infections: in vitro characteristics.
@en
type
label
Tedizolid for the management of human infections: in vitro characteristics.
@en
prefLabel
Tedizolid for the management of human infections: in vitro characteristics.
@en
P2093
P356
P1476
Tedizolid for the management of human infections: in vitro characteristics
@en
P2093
Gary E Zurenko
Jeffrey B Locke
Kenneth Bartizal
P304
P356
10.1093/CID/CIT616
P407
P478
58 Suppl 1
P50
P577
2014-01-01T00:00:00Z